Literature DB >> 3940251

Neurotensin increases colonic motility.

K Thor, S Rosell.   

Abstract

The effects of neurotensin on colonic motility were investigated in 6 healthy volunteers (rectosigmoid area) and 7 patients (ascending colon and at the splenic flexure). Neurotensin (12 pmol/kg X min) infused intravenously for 30 min increased the duration of the contractions to 76% in the ascending colon and 46% in the rectosigmoid area. In the postinfusion period, the values were 42% and 67%, respectively. The motor activity did not change significantly at the splenic flexure. During the infusion period, the motility index increased from 870 to 4500 in the ascending colon and from 332 to 1700 in the rectosigmoid area. In the rectosigmoid area, however, a statistically significant increase was recorded first after cessation of the infusion. All subjects reported increased sensation of intestinal movement after intravenous infusion of neurotensin, and the patients discharged a median volume of 600 ml of bowel contents 20 min after cessation of the infusion. The data show that neurotensin causes an increase in colonic motility in the ascending colon of patients and also, after a latent period, in the rectosigmoid area of healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940251     DOI: 10.1016/0016-5085(86)90070-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  21 in total

1.  Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene.

Authors:  Xiaofu Wang; Pat Gulhati; Jing Li; Paul R Dobner; Heidi Weiss; Courtney M Townsend; B Mark Evers
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

Review 2.  Physiology and pathophysiology of colonic motor activity (1).

Authors:  S K Sarna
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

3.  Gastrointestinal myoelectric and clinical patterns of recovery after laparotomy.

Authors:  J H Waldhausen; M E Shaffrey; B S Skenderis; R S Jones; B D Schirmer
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

4.  Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells.

Authors:  Qingding Wang; Yuning Zhou; B Mark Evers
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

5.  Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome.

Authors:  R J Geer; W O Richards; T M O'Dorisio; E O Woltering; S Williams; D Rice; N N Abumrad
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

6.  Motor responsiveness of proximal and distal human colonic muscle layers to carbachol and neurotensin.

Authors:  M A Maselli; A L Piepoli; G Riezzo; F Pezzolla
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

7.  Expression of neurotensin messenger RNA in a human carcinoid tumor.

Authors:  B M Evers; J Ishizuka; C M Townsend; S Rajaraman; J C Thompson
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

8.  Developmental expression of the neurotensin gene in the rat liver.

Authors:  B M Evers; S Rajaraman; D H Chung; C M Townsend; X Wang; K Graves; J C Thompson
Journal:  Ann Surg       Date:  1993-08       Impact factor: 12.969

9.  The neurotensin gene is a downstream target for Ras activation.

Authors:  B M Evers; Z Zhou; P Celano; J Li
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

10.  Neurotensin regulates growth of human pancreatic cancer.

Authors:  J Ishizuka; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1993-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.